$MRK

KEYNOTE-361 trial evaluating KEYTRUDA in combination with chemotherapy for the first-line treatment of patients with advanced or metastatic urothelial carcinoma (bladder cancer) did not meet its pre-specified dual primary endpts of OS or PFS, vs SOC